These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 2932197)

  • 1. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
    Maguire ED; Wallis RB
    Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
    Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
    Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation.
    Butler KD; Maguire ED; Smith JR; Turnbull AA; Wallis RB; White AM
    Thromb Haemost; 1982 Feb; 47(1):46-9. PubMed ID: 6461944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
    Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
    Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors.
    Barrett PA; Butler KD; Shand RA; Wallis RB
    Thromb Haemost; 1986 Dec; 56(3):311-7. PubMed ID: 3105107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
    De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
    Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
    Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
    Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective and nonselective inhibition of thromboxane formation.
    FitzGerald GA; Oates JA
    Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
    Sincholle D; Coquelet C; Bonne C
    Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
    Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
    Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs.
    DeCampli WM; Goodwin D; Kosek JC; Handen CE; Mitchell RS; Miller DC
    Ann Thorac Surg; 1986 Dec; 42(6):690-6. PubMed ID: 3789860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
    Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
    Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of modulation of prostanoid metabolism on the thoracic platelet accumulation induced by intravenous administration of collagen in the guinea-pig.
    Butler KD; Shand RA; Wallis RB
    Thromb Haemost; 1986 Dec; 56(3):263-7. PubMed ID: 3105104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.